Uitgave bijlage 1/2021
Guidelines on COVID-19 and heart disease
Inhoudsopgave (5 Artikelen)
- Open Access
- Introduction
Four guidelines on cardiovascular complications and cardiovascular disease, prognosis and treatment in COVID‑19
H. J. Siebelink, C. W. Jansen, E. Belfroid, J. Hoogervorst-Schilp
- Open Access
- Guideline
How often and to what extent do admitted COVID-19 patients have signs of cardiac injury?
M. A. W. Habets, H. N. Sturkenboom, R. A. Tio, E. Belfroid, J. Hoogervorst-Schilp, H. J. Siebelink, C. W. Jansen, P. C. Smits
- Open Access
- Guideline
Impact of cardiovascular disease and cardiovascular risk factors in hospitalised COVID-19 patients
L. S. D. Jewbali, J. Hoogervorst-Schilp, E. Belfroid, C. W. Jansen, F. W. Asselbergs, H. J. Siebelink
- Open Access
- Guideline
The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patients
R. R. J. van Kimmenade, E. Belfroid, J. Hoogervorst-Schilp, H. J. Siebelink, C. W. Janssen, Y. Pinto
- Open Access
- Guideline
Effect of anticoagulant therapy in COVID-19 patients
R. G. Tieleman, F. A. Klok, E. Belfroid, J. Hoogervorst-Schilp, I. Schalkers, C. W. Jansen, H. J. Siebelink
